ESLA

Insider Trades

Name	Value	Action	Price	Current Price
Xu JiandongChief Financial Officer $1.3k1k shares BuyOct 7, 2025 $1.33 --
Xu JiandongChief Financial Officer $1.2k1k shares BuySep 22, 2025 $1.16 --
Xu JiandongChief Financial Officer $104100 shares BuySep 11, 2025 $1.04 --

News

businesswire.comEstrella Immunopharma to Participate in the D. Boral Capital Global Conferencebusinesswire.comMay 5

businesswire.comEstrella Immunopharma, Inc. (NASDAQ: ESLA) Receives Initiating Coverage with a Valuation of $12.00/Share from Zacks Small-Cap Researchbusinesswire.comMar 23

Trade ESLA

About Estrella Immunopharma, Inc.

Estrella Immunopharma, Inc. is an early-stage biopharmaceutical enterprise focused on creating T-cell therapies for various blood cancers and solid tumors, with its primary activities centered in the United States. The company's lead investigational drugs include EB103, which is in preclinical development for diffuse large B-cell lymphoma, and EB104, intended for the treatment of both diffuse large B-cell lymphoma and acute lymphocytic leukemia. Estrella also maintains a collaborative agreement with Imugene Limited, working together to develop solid tumor therapies that integrate Imugene's CF33-CD19t product candidate with Estrella's EB103. The company is based in Emeryville, California.

CEO: Cheng Liu
IPO Date: Sep 14, 2021

Market Data

Open: $1.03
High: $1.03
Low: $0.95
Volume: 51.5K
Avg Volume: 85.1K
52W High: $3.15
52W Low: $0.78

Valuation

Market Cap: $41M
Enterprise Value: $39M
Dividend Yield: 0.00%

Financials

Free Cash Flow: $-1.8M
Revenue: $0
Net Income: $-13M
Cash: $1.4M
Debt: $0

Events

EarningsSep 2

EPS est. -0.0793